disitamab vedotin
seagen,rongchang pharma,spdr s&p biotech,ishares biotechnology,remegen
['bladder', 'disitamab', ' vedo', '$ibb', 'remegen', '$xbi']
$regmy remegen presents promising outcomes of disitamab vedotin in treating bladder cancer at asco 2023. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt